Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. John P. Chalmers
Prof. Lars Ryden,
By John P Chalmers, (Sydney, Australia)View Discussant report by Lars Ryden, FESC
Open the PresentationWatch the Webcast
List of Authors: John Chalmers 1() on behalf of the ADVANCE-ON Collaborative Group (1) The George Institute for Global Health, Sydney, Australia
BackgroundThe Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, was a 2x2 factorial trial whose blood pressure lowering arm demonstrated that the combination of perindopril-indapamide reduced all-cause mortality by 14%, cardiovascular death by 18% and vascular events by 9% in patients with type 2 diabetes. We present here the results of post-trial follow-up, conducted to determine whether these benefits were sustained.MethodsSurvivors, previously randomly assigned to perindopril-indapamide or placebo were invited to post-trial follow-up. Primary outcomes were all-cause mortality and major macrovascular events (myocardial infarction, stroke and death from a cardiovascular cause). Effects on pre-specified endpoints were compared according to previous randomised treatment. (ClinicalTrials.Gov NCT 0094286)ResultsBaseline characteristics of 11140 patients originally randomised, and 8494 who contributed to post-trial follow-up for a median of 5.9 years, were similar. Differences in blood pressure between the two groups disappeared by the first post-randomisation visit. The reductions in all-cause death and cardiovascular death recorded during active treatment were sustained to the end of post-trial follow-up (hazard ratios [95% confidence intervals] 0.91[0.84-0.99], p=0.03 and 0.88[0.77-0.99], p=0.04) respectively, but were diminished. The reductions in major macrovascular events were not significant (0.92[0.85-1.00], p=0.06)ConclusionsThese results emphasise the importance of active blood pressure lowering in patients with type 2 diabetes in both the short term and the long term in order to maximise survival and cardiovascular protection.
By Lars Ryden, FESC (Stockholm, Sweden)See Presenter abstract
Open the presentationWatch the Webcast
Clinical Trial Update Hot Line: Interventions and drug therapy
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved